Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22714741 | 0.94 | CHRM2 (0.42) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL22394916 | 0.84 | CHRM2 (0.37) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL15716251 | 0.84 | CHRM2 (0.42) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL25151364 | 0.83 | KDM1A (0.40) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL5140938 | 0.83 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL22638812 | 0.82 | HSD17B10 (0.45) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL21274184 | 0.81 | GRIN2B (0.43) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL31637402 | 0.81 | HSD11B1 (0.35) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL24423575 | 0.81 | NR1H2 (0.44) | CHRM2CHRM1CHRM3HPGDEPHX2 | |
| SCHEMBL31379550 | 0.81 | EPHX1 (0.42) | CHRM2CHRM1CHRM3HPGDEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739682-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | Janssen Pharmaceutica NV (BE) | 2026-05-13 | — | — | EP | disclosed |
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4288426-B1 | QUINOXALINE DERIVATIVES AND USES THEREOF | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-04 | — | — | EP | disclosed |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HUFF SARAH ELIZABETH (US) | 2025-11-20 | — | — | US | disclosed |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | REMIX THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-12447153-B2 | HER2 mutation inhibitors | PFIZER INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| WO-2025008058-A1 | 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS | JANSSEN PHARMACEUTICA NV (BE) | 2025-01-09 | — | — | WO | disclosed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | disclosed |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-02-01 | — | — | US | disclosed |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | AICURIS GMBH & CO. KG (DE) | 2022-02-01 | — | — | US | disclosed |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-10-28 | — | — | US | disclosed |
| EP-3840747-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2021-06-30 | — | — | EP | disclosed |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-06-17 | — | — | US | disclosed |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO. KG (DE) | 2021-06-17 | — | — | US | disclosed |
| WO-2020210630-A1 | TRICYCLIC DEGRADERS OF IKAROS AND AIOLOS | C4 THERAPEUTICS, INC. (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-3704119-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AiCuris GmbH & Co. KG (DE) | 2020-09-09 | — | — | EP | disclosed |
| WO-2020041100-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250082633-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | RBM17, SNRPA, SNRPA1 | CHRM2 4815/4885CHRM1 4610/4885CHRM3 4393/4885 |
| US-20250332173-A1 | COMPOUNDS AND METHODS FOR MODULATING NUCLEIC ACID SPLICING | SNRPA, NSUN2, SNRPA1 | CHRM2 4881/4885CHRM1 4848/4885CHRM3 4757/4885 |
| US-20250353841-A1 | HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, ATXN2 | CHRM2 4596/4885CHRM1 4752/4885CHRM3 4727/4885 |
| US-20210179608-A1 | NOVEL, HIGHLY ACTIVE PYRAZOLO-PIPERIDINE SUBSTITUTED INDOLE-2-CARBOXAMIDES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | CDK2, HCCS, BRD4 | CHRM2 4868/4885CHRM1 4801/4885CHRM3 4837/4885 |
| US-12576087-B2 | Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors | IDO1, IDO2, TPH1 | CHRM2 572/4885CHRM1 408/4885CHRM3 633/4885 |
| US-20210330676-A1 | NOVEL ARYLOXYPIPERIDINE PYRAZOLE COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS | IDO1, IDO2, KYNU | CHRM2 2330/4885CHRM1 2873/4885CHRM3 2294/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | CHRM2 4394/4885CHRM1 4263/4885CHRM3 4638/4885 |
| US-12447153-B2 | HER2 mutation inhibitors | ERBB2, EGFR, ERBB3 | CHRM2 2009/4885CHRM1 1931/4885CHRM3 3801/4885 |
| US-11236087-B2 | Highly active pyrazolo-piperidine substituted indole-2-carboxamides active against the hepatitis B virus (HBV) | HCCS, BRD4, CDK2 | CHRM2 4865/4885CHRM1 4792/4885CHRM3 4830/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | CHRM2 4309/4885CHRM1 4030/4885CHRM3 4248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.